Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3662056rdf:typepubmed:Citationlld:pubmed
pubmed-article:3662056lifeskim:mentionsumls-concept:C0027348lld:lifeskim
pubmed-article:3662056lifeskim:mentionsumls-concept:C0027358lld:lifeskim
pubmed-article:3662056lifeskim:mentionsumls-concept:C0235063lld:lifeskim
pubmed-article:3662056lifeskim:mentionsumls-concept:C0032790lld:lifeskim
pubmed-article:3662056lifeskim:mentionsumls-concept:C0680242lld:lifeskim
pubmed-article:3662056pubmed:issue11lld:pubmed
pubmed-article:3662056pubmed:dateCreated1987-11-18lld:pubmed
pubmed-article:3662056pubmed:abstractTextThe authors compared naloxone and nalbuphine as antagonists of opioid-induced respiratory depression to determine the relative efficacies and safety of the two agents. In a double-blind, randomized fashion, 90 anesthetized patients received a mean dose of 25 micrograms/kg fentanyl during surgery. Inadequate spontaneous respirations at the end of anesthesia were treated with either naloxone 0.08 mg or nalbuphine 2.5 mg IV every 2 min while heart rate (HR), systolic and diastolic blood pressures (SBP, DBP), respiratory rate (RR), and tidal volume (TV) were measured at 2-min intervals. Arterial blood samples for analysis of PaCO2, PaO2, and pH were drawn when spontaneous ventilation resumed, and 30 and 60 min later. Narcotic antagonism and respiration were deemed adequate when TV was greater than or equal to 4 ml/kg and RR greater than or equal to 8 breaths/min. Heart rate, SBP, DBP, TV and RR were recorded, as were the occurrence of renarcotization (RR less than 8) and analgesic requirements every 5 min during the recovery room stay. Sixty of 90 patients required narcotic antagonism at the end of surgery. No patient required more than three doses (0.24 mg) of naloxone or four doses (10 mg) of nalbuphine. Both antagonists produced similar and moderate increases in SBP and HR while restoring adequate spontaneous ventilation. There were no significant differences in TV, RR, or arterial blood gases (ABGS) between the two groups after narcotic reversal.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:3662056pubmed:languageenglld:pubmed
pubmed-article:3662056pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3662056pubmed:citationSubsetAIMlld:pubmed
pubmed-article:3662056pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3662056pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3662056pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3662056pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3662056pubmed:statusMEDLINElld:pubmed
pubmed-article:3662056pubmed:monthNovlld:pubmed
pubmed-article:3662056pubmed:issn0003-2999lld:pubmed
pubmed-article:3662056pubmed:authorpubmed-author:StanleyT HTHlld:pubmed
pubmed-article:3662056pubmed:authorpubmed-author:PaceN LNLlld:pubmed
pubmed-article:3662056pubmed:authorpubmed-author:BaileyP LPLlld:pubmed
pubmed-article:3662056pubmed:authorpubmed-author:ClarkN JNJlld:pubmed
pubmed-article:3662056pubmed:authorpubmed-author:van...lld:pubmed
pubmed-article:3662056pubmed:authorpubmed-author:EastK AKAlld:pubmed
pubmed-article:3662056pubmed:authorpubmed-author:van de PolPPlld:pubmed
pubmed-article:3662056pubmed:authorpubmed-author:ClissoldM AMAlld:pubmed
pubmed-article:3662056pubmed:authorpubmed-author:RozendaalWWlld:pubmed
pubmed-article:3662056pubmed:issnTypePrintlld:pubmed
pubmed-article:3662056pubmed:volume66lld:pubmed
pubmed-article:3662056pubmed:ownerNLMlld:pubmed
pubmed-article:3662056pubmed:authorsCompleteYlld:pubmed
pubmed-article:3662056pubmed:pagination1109-14lld:pubmed
pubmed-article:3662056pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3662056pubmed:meshHeadingpubmed-meshheading:3662056-...lld:pubmed
pubmed-article:3662056pubmed:meshHeadingpubmed-meshheading:3662056-...lld:pubmed
pubmed-article:3662056pubmed:meshHeadingpubmed-meshheading:3662056-...lld:pubmed
pubmed-article:3662056pubmed:meshHeadingpubmed-meshheading:3662056-...lld:pubmed
pubmed-article:3662056pubmed:meshHeadingpubmed-meshheading:3662056-...lld:pubmed
pubmed-article:3662056pubmed:meshHeadingpubmed-meshheading:3662056-...lld:pubmed
pubmed-article:3662056pubmed:meshHeadingpubmed-meshheading:3662056-...lld:pubmed
pubmed-article:3662056pubmed:meshHeadingpubmed-meshheading:3662056-...lld:pubmed
pubmed-article:3662056pubmed:meshHeadingpubmed-meshheading:3662056-...lld:pubmed
pubmed-article:3662056pubmed:meshHeadingpubmed-meshheading:3662056-...lld:pubmed
pubmed-article:3662056pubmed:meshHeadingpubmed-meshheading:3662056-...lld:pubmed
pubmed-article:3662056pubmed:meshHeadingpubmed-meshheading:3662056-...lld:pubmed
pubmed-article:3662056pubmed:meshHeadingpubmed-meshheading:3662056-...lld:pubmed
pubmed-article:3662056pubmed:year1987lld:pubmed
pubmed-article:3662056pubmed:articleTitleAntagonism of postoperative opioid-induced respiratory depression: nalbuphine versus naloxone.lld:pubmed
pubmed-article:3662056pubmed:affiliationDepartment of Anesthesiology, University of Utah Health Sciences Center, Salt Lake City.lld:pubmed
pubmed-article:3662056pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3662056pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3662056pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3662056pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:3662056pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed